Xiaoxin Cai

1.3k total citations
16 papers, 1.0k citations indexed

About

Xiaoxin Cai is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Xiaoxin Cai has authored 16 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Pediatrics, Perinatology and Child Health and 5 papers in Pharmacology. Recurrent topics in Xiaoxin Cai's work include Drug Transport and Resistance Mechanisms (9 papers), Pharmacological Effects and Toxicity Studies (5 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Xiaoxin Cai is often cited by papers focused on Drug Transport and Resistance Mechanisms (9 papers), Pharmacological Effects and Toxicity Studies (5 papers) and Pharmacogenetics and Drug Metabolism (4 papers). Xiaoxin Cai collaborates with scholars based in United States, China and United Kingdom. Xiaoxin Cai's co-authors include Xiaoyan Chu, Raymond Evers, Jocelyn Yabut, Grace Chan, David C. Evans, Regina W. Wang, Thomayant Prueksaritanont, Iain P. Fraser, Dennis Dean and Matthew P. Braun and has published in prestigious journals such as Journal of Biological Chemistry, American Journal Of Pathology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Xiaoxin Cai

16 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaoxin Cai United States 14 578 388 340 155 138 16 1.0k
Yoshitane Nozaki Japan 16 902 1.6× 336 0.9× 497 1.5× 193 1.2× 108 0.8× 26 1.3k
Vikram Arya United States 18 479 0.8× 280 0.7× 359 1.1× 177 1.1× 90 0.7× 50 1.1k
Kelly Bleasby United States 16 674 1.2× 236 0.6× 349 1.0× 240 1.5× 57 0.4× 21 1.1k
Mitchell E. Taub United States 19 908 1.6× 390 1.0× 464 1.4× 354 2.3× 67 0.5× 51 1.4k
Annick Seithel Germany 6 765 1.3× 251 0.6× 371 1.1× 214 1.4× 51 0.4× 7 1.1k
Michel Eichelbaum Germany 11 560 1.0× 349 0.9× 388 1.1× 150 1.0× 97 0.7× 14 931
Suparat Khamdang Japan 10 749 1.3× 183 0.5× 388 1.1× 283 1.8× 123 0.9× 12 1.4k
Landry K. Kamdem United States 12 338 0.6× 326 0.8× 229 0.7× 162 1.0× 60 0.4× 21 898
Annikka Kalliokoski Finland 9 710 1.2× 423 1.1× 396 1.2× 203 1.3× 46 0.3× 12 1.2k
Gustav Ahlin Sweden 7 813 1.4× 245 0.6× 389 1.1× 265 1.7× 45 0.3× 8 1.1k

Countries citing papers authored by Xiaoxin Cai

Since Specialization
Citations

This map shows the geographic impact of Xiaoxin Cai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoxin Cai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoxin Cai more than expected).

Fields of papers citing papers by Xiaoxin Cai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoxin Cai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoxin Cai. The network helps show where Xiaoxin Cai may publish in the future.

Co-authorship network of co-authors of Xiaoxin Cai

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoxin Cai. A scholar is included among the top collaborators of Xiaoxin Cai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoxin Cai. Xiaoxin Cai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Cai, Xiaoxin, Guoquan Chen, Haiping Wang, Xuan Wang, & Congli Hu. (2025). Pharmacovigilance insights into drug-associated venous thromboembolism. International Journal of Surgery. 111(11). 7677–7685. 1 indexed citations
2.
He, Xin, Zhongyang Zhao, Jie Kang, et al.. (2020). High-Fat Diet–Induced Functional and Pathologic Changes in Lacrimal Gland. American Journal Of Pathology. 190(12). 2387–2402. 39 indexed citations
3.
Bu, Jinghua, Jingwen Yu, Yang Wu, et al.. (2020). Hyperlipidemia Affects Tight Junctions and Pump Function in the Corneal Endothelium. American Journal Of Pathology. 190(3). 563–576. 17 indexed citations
4.
Bu, Jinghua, Yang Wu, Xiaoxin Cai, et al.. (2019). Hyperlipidemia induces meibomian gland dysfunction. The Ocular Surface. 17(4). 777–786. 58 indexed citations
5.
Li, Sanming, Jing Zhou, Jinghua Bu, et al.. (2017). Ectodysplasin A protein promotes corneal epithelial cell proliferation. Journal of Biological Chemistry. 292(32). 13391–13401. 23 indexed citations
6.
Wu, Yang, Jinghua Bu, Yiran Yang, et al.. (2017). Therapeutic Effect of MK2 Inhibitor on Experimental Murine Dry Eye. Investigative Ophthalmology & Visual Science. 58(11). 4898–4898. 12 indexed citations
7.
Prueksaritanont, Thomayant, Xiaoyan Chu, Radha Railkar, et al.. (2016). Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clinical Pharmacology & Therapeutics. 101(4). 519–530. 109 indexed citations
8.
9.
Prueksaritanont, Thomayant, Xiaoyan Chu, Raymond Evers, et al.. (2014). Pitavastatin is a more sensitive and selective organic anion‐transporting polypeptide1Bclinical probe than rosuvastatin. British Journal of Clinical Pharmacology. 78(3). 587–598. 144 indexed citations
10.
Chu, Xiaoyan, Xiaoxin Cai, Donghui Cui, et al.. (2013). In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters. Drug Metabolism and Disposition. 41(3). 668–681. 48 indexed citations
11.
Reitman, Marc L., Xiaoyan Chu, Xiaoxin Cai, et al.. (2010). Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug–Drug Interaction Trial Design. Clinical Pharmacology & Therapeutics. 89(2). 234–242. 133 indexed citations
12.
Chu, Xiaoyan, Yuexia Liang, Xiaoxin Cai, et al.. (2008). Metabolism and Renal Elimination of Gaboxadol in Humans: Role of UDP-Glucuronosyltransferases and Transporters. Pharmaceutical Research. 26(2). 459–468. 16 indexed citations
13.
Chu, Xiaoyan, Kelly Bleasby, Jocelyn Yabut, et al.. (2007). Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein. Journal of Pharmacology and Experimental Therapeutics. 321(2). 673–683. 143 indexed citations
14.
Chu, Xiaoyan, John R. Strauss, Jing Li, et al.. (2006). Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2). Journal of Pharmacology and Experimental Therapeutics. 317(2). 579–589. 105 indexed citations
15.
Cai, Xiaoxin, Regina W. Wang, Richard W. Edom, et al.. (2004). VALIDATION OF (-)-N-3-BENZYL-PHENOBARBITAL AS A SELECTIVE INHIBITOR OF CYP2C19 IN HUMAN LIVER MICROSOMES. Drug Metabolism and Disposition. 32(6). 584–586. 22 indexed citations
16.
Chen, Qing, Jason S. Ngui, George A. Doss, et al.. (2002). Cytochrome P450 3A4-Mediated Bioactivation of Raloxifene:  Irreversible Enzyme Inhibition and Thiol Adduct Formation. Chemical Research in Toxicology. 15(7). 907–914. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshitane Nozaki Breakdown of academic impact, for papers by Vikram Arya Breakdown of academic impact, for papers by Kelly Bleasby Breakdown of academic impact, for papers by Mitchell E. Taub Breakdown of academic impact, for papers by Annick Seithel Breakdown of academic impact, for papers by Michel Eichelbaum Breakdown of academic impact, for papers by Suparat Khamdang Breakdown of academic impact, for papers by Landry K. Kamdem Breakdown of academic impact, for papers by Annikka Kalliokoski Breakdown of academic impact, for papers by Gustav Ahlin
Rankless by CCL
2026